Data_Sheet_1_Vaccination with SARS-CoV-2 inactivated vaccines reduced the risk of anxiety and depression in a population majored by health care workers during the recent omicron variant outbreak.doc

BackgroundThe mental health status of the population majored by health care workers in China during the omicron variant outbreak remains unknown. Furthermore, the effect of COVID-19-inactivated vaccines on mental health is yet to be investigated.MethodsA cross-sectional, online survey study was conducted from 12–20 April, 2022. The prevalence of symptoms of depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale.ResultsResponses from a total of 1,387 participants were analyzed, 39.7% of which reported symptoms of mental health illness. The incidence of anxiety (30.4% vs. 48.4%, p ConclusionOur findings increase the awareness of the high incidence of mental health illness symptoms during the omicron variant outbreak despite previous experiences with the COVID-19 pandemic, and vaccination is suggested to reduce the risk of anxiety and depression.</p

Table_1_Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study.XLSX

Background: The aim of this study was to investigate the impact of proton pump inhibitor (PPI) therapy on complications and prognosis in cirrhosis patients with and without acute-on-chronic liver failure (ACLF).Materials and Methods: Cirrhosis patients with acute decompensation (AD) (n = 489) admitted in our center were enrolled in this prospective observational cohort study. According to treatment received, patients were identified as users or nonusers of PPI. Clinical and laboratory data, complications during hospitalization, and overall survival were recorded in all the patients.Results: Of the 489 patients, 299 (61.1%) patients received PPI therapy. The logistic regression analysis showed that age, albumin, history of previous hepatic encephalopathy (HE), and the chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score were independent risk factors for HE in patients with decompensated cirrhosis [odds ratio (OR) = 1.07, 95% CI: 1.03–1.12, p = 0.001; OR = 1.13, 95% CI: 1.04–1.24, p = 0.006; OR = 242.52, 95% CI: 40.17–1464.11, p Conclusion: PPI use does not appear to increase mortality or the risk of HE and SBP in the hospitalized cirrhosis patients with and without ACLF.</p

Multidrug-resistant bacterial infections in cirrhotic patients: an epidemiological study

Background: The purpose of this study is to describe the epidemiological features of bacterial infections caused by multidrug-resistant (MDR) bacteria in cirrhotic patients and their impact on mortality. Methods: A retrospective study of cirrhotic patients with culture-confirmed bacterial infections was performed between 2011 and 2017. Results: A total of 635 episodes in 563 patients with cirrhosis were included. Bacterial infections caused by MDR isolates accounted for 44.1% (280/635) of the episodes, nearly half of which were hospital acquired (48.4%). The most common MDR isolation site was the respiratory tract (36.4%, 102 episodes), followed by the abdominal cavity (35.4%, 99 episodes). Of the MDR isolates, carbapenem-resistant Enterobacteriaceae (CRE) (91 episodes) were the most common. Patients infected with MDR bacteria had significantly higher mortality than those not infected (25.1% vs 17.4%, p = 0.025). However, this increased mortality could be largely attributed to methicillin-resistant Staphylococcus aureus (MRSA). After adjustment for age, sex, and the model for end-stage liver disease (MELD) score, only MRSA infection was an independent risk factor for 28-day mortality in the multivariable Cox proportional hazard regression model analysis (HR, 2.964, 95% CI (1.175–7.478), p = 0.021). Conclusions: MDR bacterial infections, especially CRE, have become frequent in patients with cirrhosis in recent years, with MRSA infections significantly increasing short-term mortality.</p

Additional file 1 of The burden and predictors of 30-day unplanned readmission in patients with acute liver failure: a national representative database study

Supplementary Material

Comparison of patient cumulative survival between ALSS-LT group and LT group.

<p>(<i>P</i> = 0.406) (ALSS, artificial liver support system; LT, liver transplantation).</p

Intraoperative blood loss, intubation and ICU staying time in the artificial liver support system (ALSS)-liver transplantation (LT) group and LT group.

<p>Intraoperative blood loss, intubation and ICU staying time in the artificial liver support system (ALSS)-liver transplantation (LT) group and LT group.</p

Changes of key laboratory parameters pre- and post-artificial liver support system (ALSS) treatment in different subgroups.

<p>Removal rate was calculated as: (pre-treatment concentration—post-treatment concentration)/pre-treatment concentration.</p><p>Abbreviations: PE, plasma exchange; TB, total bilirubin; Cr, creatinine; PT, prothrombin time.</p

Liver function and model for End-Stage Liver Disease (MELD) score before artificial liver support system (ALSS) and before liver transplantation (LT).

<p>Abbreviations: TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acid;</p

The baseline patient characteristics.

<p>Abbreviations: ALSS, artificial liver support system; LT, liver transplantation; TB, total bilirubin; MELD, model for End-Stage Liver Disease; HBV, hepatitis B virus.</p

Additional file 1 of One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection

Additional file 1 Table S1: Distribution of residual abnormalities patterns at different time points. Figure S1: Radiologic patterns observed in follow-up chest CTs of patients recovered from COVID-19